利奇迪亚
估值 各估值倍数与自身5年区间的对比
同业对比 Drug Manufacturers - Specialty & Generic
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 利奇迪亚 (LQDA) | 3.07B | 24.54 | 15.76 | 0.00% |
| Takeda Pharmaceutical (TAK) | 62.84B | -59.43 | 1.31 | 3.04% |
| Teva Pharmaceutical Industries (TEVA) | 48.40B | 69.17 | 6.24 | 0.00% |
| Haleon (HLN) | 44.55B | 21.06 | 2.05 | 1.88% |
| Zoetis (ZTS) | 32.80B | 12.95 | 10.42 | 2.60% |
| United Therapeutics (UTHR) | 22.87B | 19.10 | 3.57 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算38.4%。
合理价值
Liquidia Corp earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 31% premium over our quantitative fair value estimate of $21.17 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.
The firm's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 7.6% lies in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.
On a different note, the firm's solid growth is reassuring. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. The firm's revenue 5-year growth, for example, sits in the top 1% globally. Relatively strong trailing five-year revenue growth suggests a compelling trajectory for future sales and earnings, which, despite our unfavorable price/fair value ratio, is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
经济护城河
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:59:43 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
利奇迪亚 讨论区 0 条评论